3B Blackbio DX Ltd
3B Blackbio DX Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on 3B Blackbio DX Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Q1 2026-27 Consolidated EBITDA: ₹1,466.54 Lakh, down from ₹1,619.43 Lakh in Q1 2025-26 (includes Coris' negative EBITDA of ₹(352.24) Lakh).
From 3B Blackbio DX Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. 60.5%.
- Export sales in Q1 2026-27: ₹596.28 Lakh vs ₹430.90 Lakh in Q1 2025-26 — 38% growth.
- 3B Standalone Q1 sales grew by 19%.
- MDx Division revenue (excluding Coris): ₹2,342.90 Lakh vs ₹1,996.06 Lakh — about 17.4% growth.
- Coris Q1 2026-27 revenue: €796K (~₹862.83 Lakh), slight increase vs previous year.
- Sales model projection: Contractual/Reagent rental expected to contribute 20%-25% of total revenue long term.
2 more points management made on revenue & sales performance
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is currently operating at ~65% installed capacity, with potential to scale to 100% during seasonal spikes; lean season utilization is ~50%, allowing flexibility. (Page 45)
- No explicit new plant or project capex details are provided.
- Funds will be deployed partly in the joint venture in Manchester, UK, as needed. (Page 45)
- Long-term contracts and M&A, including acquisition of Coris BioConcept SRL (completed 29th August 2025), are strategic moves for growth; no new capex amounts specified. (Pages 29, 45)
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Coris BioConcept SRL received a HAT order of EUR 1.41M to be supplied in Q3, December 2026 (Page 29).
- The company had a Belgium Government Order for HAT valued at EUR 6.0M received in February 2024 to be supplied over 4 years (Page 29).
- The Middle East market shows strong order inflow reflecting growing traction (Page 24).
2 more points management made on order book & pipeline
3B Blackbio DX Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Others in Healthcare Services this season
- KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- Thyrocare Technologies Ltd (Q1 FY27)
Pathology business grew ~27%; franchisee business grew ~23-27% YoY, reflecting strong volume growth. Key concall takeaways from Thyrocare Technologies Ltd's Q1…
- Krsnaa Diagnost. (Q1 FY27)
. Key concall takeaways from Krsnaa Diagnost.'s Q1 FY27 earnings call — and how it ranks against sector peers.
- Artemis Medicare (Q1 FY27)
Potential to reach INR 2,000 crores topline from Gurgaon alone within 3-5 years. Key concall takeaways from Artemis Medicare's Q1 FY27 earnings call — and how…
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q1 FY27 results?
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Q1 2026-27 Consolidated EBITDA: ₹1,466.54 Lakh, down from ₹1,619.43 Lakh in Q1 2025-26 (includes Coris' negative EBITDA of ₹(352.24) Lakh).
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is currently operating at ~65% installed capacity, with potential to scale to 100% during seasonal spikes; lean season utilization is ~50%, allowing flexibility.
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.